Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 12/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.38 |
| ▸ | USP2 | O75604 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16111934 | 0.82 | ALDH1A1 (0.36) | CYP1A2CYP3A4CYP2C9CYP2C19USP2 | |
| SCHEMBL9054636 | 0.80 | HSD17B10 (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19USP2 | |
| SCHEMBL364678 | 0.72 | FDPS (0.56) | CYP1A2CYP3A4CYP2C9CYP2C19USP2 | |
| SCHEMBL23346841 | 0.69 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C9CYP2C19USP2 | |
| SCHEMBL16112157 | 0.67 | CYP1A2 (0.36) | CYP1A2CYP3A4CYP2C9CYP2C19USP2 | |
| SCHEMBL26607631 | 0.67 | CYP1A2 (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19USP2 | |
| SCHEMBL9690911 | 0.66 | CYP1A2 (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19USP2 | |
| SCHEMBL26623101 | 0.65 | CCNA2 (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19USP2 | |
| SCHEMBL26597008 | 0.65 | CYP1A2 (0.37) | CYP1A2CYP3A4CYP2C9CYP2C19USP2 | |
| SCHEMBL26639161 | 0.64 | CCNA2 (0.41) | CYP1A2CYP3A4CYP2C9CYP2C19USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112920092-B | Prodrugs of glutamine analogues | 约翰霍普金斯大学 | 2024-04-26 | — | — | CN | disclosed |
| US-11926640-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-03-12 | — | — | US | disclosed |
| EP-3328827-B1 | PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230009398-A1 | NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2023-01-12 | — | — | US | disclosed |
| EP-3692015-B1 | NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2022-08-24 | — | — | EP | disclosed |
| US-11185534-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2021-07-08 | — | — | US | disclosed |
| CN-112920092-A | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-06-08 | — | — | CN | disclosed |
| US-10954257-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| CN-108290827-B | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-01-01 | — | — | CN | disclosed |
| US-10738066-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200230111-A1 | PRODRUGS OF GLUTAMINE ANALOGS | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2020-07-23 | — | — | US | disclosed |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-10336778-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| WO-2018144718-A1 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2017023774-A9 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | WO | disclosed |
| US-6946457-B2 | Methods of treating sickle cell disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2005-09-20 | — | — | US | disclosed |
| US-20040204430-A1 | Methods of treating sickle cell disease | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | CYP1A2 1146/4885CYP3A4 612/4885CYP2C9 227/4885 |
| US-10738066-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | CYP1A2 1266/4885CYP3A4 695/4885CYP2C9 316/4885 |
| US-20200230111-A1 | PRODRUGS OF GLUTAMINE ANALOGS | ASNS, GLUL, GLS2 | CYP1A2 3016/4885CYP3A4 664/4885CYP2C9 1768/4885 |
| US-11926640-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | CYP1A2 1266/4885CYP3A4 695/4885CYP2C9 316/4885 |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | CYP1A2 1266/4885CYP3A4 695/4885CYP2C9 316/4885 |
| US-10336778-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | CYP1A2 1266/4885CYP3A4 695/4885CYP2C9 316/4885 |
| US-10954257-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | CYP1A2 1266/4885CYP3A4 695/4885CYP2C9 316/4885 |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | CYP1A2 1266/4885CYP3A4 695/4885CYP2C9 316/4885 |
| US-11185534-B2 | Prodrugs of glutamine analogs | ASNS, GLUL, GLS2 | CYP1A2 3016/4885CYP3A4 664/4885CYP2C9 1768/4885 |
| US-20230009398-A1 | NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF | GLUL, PDCD1, CD274 | CYP1A2 4536/4885CYP3A4 4567/4885CYP2C9 3782/4885 |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | CYP1A2 1266/4885CYP3A4 695/4885CYP2C9 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.